Press releases
  • myEDIT-B is the world’s first clinically validated test for the differential diagnosis between bipolar disorder and unipolar depression
  • myEDIT-B…
Read more
Press releases
  • SYNLAB’s myEDIT-B is the world’s first blood-based test for the differential diagnosis between bipolar disorder and unipolar depression
  • myEDIT-B…
Read more
Press releases
  • Cinven to launch public acquisition offer to all shareholders at a price of €10.00 per SYNLAB share in cash
  • SYNLAB knows Cinven well as a…
Read more
Press releases

SYNLAB (FSE: SYAB), the leader in medical diagnostic services and specialty testing in Europe, has agreed to sell its veterinary diagnostics business…

Read more
Press releases
  • SYNLAB participates in largest ever multi-national study to determine variations in lipid profiles to improve understanding of cardiovascular risk…
Read more
Press releases
  • SYNLAB invests €8 million to build a new 4000m2 medical care centre within Florence’s Manifattura Tabacchi
  • The new centre will offer a wide range…
Read more
Press releases
  • SYNLAB moves to new city centre location at Schwanthalerhöhe in Munich, increases laboratory space to 6,000 square metres and modernises the…
Read more
Press releases
  • Launched in Spain and Colombia in 2020, myBIOME is an innovative gut microbiome examination based on technology developed by Microba’s leading…
Read more
Press releases

Hosting its 2022 Medical Congress, SYNLAB builds upon its unique diagnostic expertise and brings together medical experts from across the globe to…

Read more
Press releases
  • Building on SYNLAB’s clearly defined ESG focus areas SYNLAB Green, SYNLAB Care, and SYNLAB Citizenship, as well as its commitment to the United…
Read more